Cato BioVentures is the venture capital affiliate of Cato Research Ltd., a global contract research and development organization (CRO). For over 25 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotech and pharmaceutical companies to advance a robust portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, we have invested our CRO Service Capital in innovative therapeutics, medical devices and stem cell technologies that improve Pharma's Research and Development productivity. If strategic outsourcing for development and regulatory and clinical support is a core component of a company's business plan, then our investment model can make a positive difference in the company's overall success.
Our CRO Service Capital offers immediate access to a broad range of essential CRO services and expertise on a partial cash basis. The strategic CRO services often occur in a "bridge mode" and can extend our partners' internal development capabilities and financial runway at times when developmental progress matters most. Critical-time CRO services enable management teams operating on tight timelines with limited cash resources to achieve key value-added developmental and regulatory milestones with reduced reliance on the capital markets. We can tailor our CRO Service Capital solutions to our partners' needs.
We invest in opportunities at all stages of development and across multiple therapeutic areas in both private and public companies. Our goal at Cato BioVentures is to partner with our portfolio companies to make a difference in the successful outcome of your core development programs.